Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
ANAVEX LIFE SCIENCES CORP.
Company
Edwards Lifesciences Corp
Company
Wave Life Sciences, Inc.
Company
Caris Life Sciences, Inc.
Company
Frazier Life Sciences Acquisition Corp. II
Company
Oaktree Acquisition Corp. III Life Sciences
Company
ACHIEVE LIFE SCIENCES, INC.
Company
ENDRA Life Sciences Inc.
Company
Emmaus Life Sciences, Inc.
Company
TriSalus Life Sciences, Inc.
Company
INTEGRA LIFESCIENCES HOLDINGS CORP
Company
SELLAS Life Sciences Group, Inc.
Company
Bain Capital Life Sciences Fund, L.P.
Company
CV Sciences, Inc.
Company
Conexeu Sciences Inc.
Company
Primary record15
ANAVEX LIFE SCIENCES CORP. filed 4
SEC form 4 filed by ANAVEX LIFE SCIENCES CORP. (CIK 1314052) on 2026-11-06.
ANAVEX LIFE SCIENCES CORP. filed 4
SEC form 4 filed by ANAVEX LIFE SCIENCES CORP. (CIK 1314052) on 2026-11-06.
ANAVEX LIFE SCIENCES CORP. filed 4
SEC form 4 filed by ANAVEX LIFE SCIENCES CORP. (CIK 1314052) on 2026-11-06.
ANAVEX LIFE SCIENCES CORP. filed 4
SEC form 4 filed by ANAVEX LIFE SCIENCES CORP. (CIK 1314052) on 2026-11-06.
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer On November 1, 2026, th
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, each of Dr. Jiong Ma, Mr. Gautam Patel an
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 8.01. Other Events. On October 20, 2026, Anavex Life Sciences Corp. (the “Company”) issued a press release providing an update on the clinical development of blarcamesine (ANAVEX ® 2-73), including the completion of
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 8.01. Other Events. On October 15, 2026, Anavex Life Sciences Corp. (the Company ) issued a press release announcing that it received notification from the U.S. Food and Drug Administration that the Company may proc
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 5.01 Changes in Control of Registrant. As further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. ( Anavex or the Company ) held its 2026 Annual Meeting of Stockholders (the
ANAVEX LIFE SCIENCES CORP. filed 4
SEC form 4 filed by ANAVEX LIFE SCIENCES CORP. (CIK 1314052) on 2026-09-28.
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 8.01. Other Events. As previously disclosed, Anavex Life Sciences Corp. ( Anavex or the Company ) is prioritizing the advancement of its ANAVEX 2-73 (blarcamesine) clinical development pipeline in early Alzheimer s
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 8.01. Other Events. As previously disclosed, on May 20, 2026, Anavex Life Sciences Corp. ( Anavex or the Company ) received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On August 25, 2026, Anavex Life Sciences Corp. (the Company ) issued a press release reporting financial results for its third quarter ended June 30, 2026 (the Pr
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 7.01. Regulation FD Disclosure. On August 17, 2026, Anavex Life Sciences Corp. ( Anavex or the Company ) issued a press release (the Press Release ) announcing the mailing of a letter to stockholders (the Stockholde
ANAVEX LIFE SCIENCES CORP. filed 8-K
Item 7.01. Regulation FD Disclosure. On August 11, 2026, Anavex Life Sciences Corp. ( Anavex or the Company ) issued a press release announcing the filing of the Company s definitive proxy statement for its 2026 Annual M